Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone for metastatic hormone-refractory disease. Although treatment is still considered palliative in nature, studies of chemotherapy for metastatic hormone-refractory prostate cancer (HRPC) have demonstrated improved overall survival compared with older regimens as well as clinically significant improvements in important endpoints, such as quality of life and time to progression. In particular, docetaxel has emerged as first-line therapy on an every-3-week schedule for metastatic HRPC, replacing mitoxantrone, as recently reported in the TAX327 trial. Docetaxel and estramustine combinations have the disadvantage of significant cardiovascular and gastrointestinal toxicity, and further use of estramustine is likely unwarranted as first-line therapy. Future trials examining novel biologic agents and combination therapies should use single-agent docetaxel as the reference standard. The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–1512. Report on the TAX327 trial, presented at ASCO 2004, and discussed further in the text.

    Article  PubMed  CAS  Google Scholar 

  2. Petrylak DP, Tangen CM, Hussain MHA, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–1520. SWOG 9916 was presented at ASCO 2004 and is discussed further in the text.

    Article  PubMed  CAS  Google Scholar 

  3. Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999, 17:2506–2513.

    PubMed  CAS  Google Scholar 

  4. Bubley GJ, Carducci MA, Dahut W, et al.: Eligibility and response guidelines for phase III clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 1999, 17:3461–3467.

    PubMed  CAS  Google Scholar 

  5. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591–1597. One of the largest natural history studies of men who relapse following radical prostatectomy. It provides the basis for many of the estimates regarding time to progression, mortality, and development of metastatic disease in this heterogeneous population.

    Article  PubMed  CAS  Google Scholar 

  6. Eisenberger MA, Partin AW, Pound C, et al.: Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: update [abstract]. Proc ASCO 2003, 22:280.

    Google Scholar 

  7. Small EJ, Halabi S, Dawson NA, et al.: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025–1033. This phase III trial studied 250 men with biochemically relapsed prostate cancer after first-line hormonal therapy. Responders to these manipulations (>50% PSA response) had prolonged survival, although no difference in overall survival was seen between ketoconazole/hydrocortisone with antiandrogen withdrawal versus antiandrogen withdrawal alone.

    Article  PubMed  CAS  Google Scholar 

  8. Scher HI, Eisenberger M, D’Amico AV, et al.: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate specific antigen: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 2004, 22:537–556. Working group summary of guidelines for future clinical trials in terms of reporting outcomes.

    Article  PubMed  Google Scholar 

  9. Matzkin H, Eber P, Todd B, et al.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992, 70:2302–2309.

    Article  PubMed  CAS  Google Scholar 

  10. Scher HI, Kelly WK, Zhang ZF, et al.: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999, 91:244–251.

    Article  PubMed  CAS  Google Scholar 

  11. Smith DC, Dunn RL, Strawderman MS, et al.: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998, 16:1835–1843.

    PubMed  CAS  Google Scholar 

  12. Horti J, Dixon SC, Logothetis C, et al.: Increased transcriptional activity of PSA in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 1999, 79:1588–1593.

    Article  PubMed  CAS  Google Scholar 

  13. Wasilenko WJ, Palad AJ, Somers KD, et al.: Effect of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 1996, 68:259–264.

    Article  PubMed  CAS  Google Scholar 

  14. Beer TM: Advances in systemic therapy for prostate cancer: chemotherapy for androgen-independent prostate cancer [abstract]. Proc ASCO 2004, 23:225–232. This recent ASCO overview of phase II trials of single and combination agents in advanced prostate cancer provides an excellent historical summary of objective response rates, times to progression, PSA response rates, and overall survival. Any interested reader is referred to this review for primary sources of the phase II regimens.

    Google Scholar 

  15. Martel CL, Gumerlock PH, Meyers FJ, et al.: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003, 29:171–187.

    Article  PubMed  CAS  Google Scholar 

  16. Torti FM, Carter SK: The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 1980, 92:681–689.

    PubMed  CAS  Google Scholar 

  17. Schmidt JD: Chemotherapy of hormone-resistant stage D prostatic cancer. J Urol 1980, 123:797–805.

    PubMed  CAS  Google Scholar 

  18. Scott W, Johnson DE, Schmidt JE, et al.: Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J Urol 1976, 114:909–911.

    Google Scholar 

  19. Eisenberger MA, Simon R, O’Dwyer PJ, et al.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985, 3:827–841. This seminal paper from 1985 summarized the state of cytotoxic therapy in the pre-PSA era for HRPC and the failure of multiple trials to demonstrate survival benefits, often using unclear outcomes such as stable disease, and recommended methods of improving outcomes and standardization.

    PubMed  CAS  Google Scholar 

  20. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71(Suppl 3):1098–1099.

    Article  PubMed  CAS  Google Scholar 

  21. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999, 26 (Suppl 17):14–18.

    PubMed  CAS  Google Scholar 

  22. Friedland D, Cohen J, Miller R, et al.: A phase II trial of docetaxel (Taxotere) in hormone refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999, 26 (5 Suppl 17):19–23.

    PubMed  CAS  Google Scholar 

  23. Berry W, Rohrbaugh T: Phase II trial of single agent, weekly Taxotere in symptomatic, hormone-refractory prostate cancer [abstract]. Proc ASCO 1999, 18:1290.

    Google Scholar 

  24. Beer T, Pierce W, Lowe B, et al.: Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer [abstract]. Proc ASCO 2000, 19:1368.

    Google Scholar 

  25. Ellerhorst JA, Tu SM, Amato RJ, et al.: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997, 3:2371–2376.

    PubMed  CAS  Google Scholar 

  26. Millikan R, Thall PF, Lee SJ, et al.: Randomized multicenter phase II trial of two multicomponent regimens in androgenindependent prostate cancer. J Clin Oncol 2003, 21:878–883.

    Article  PubMed  CAS  Google Scholar 

  27. Khan MA, Carducci MA, Partin AW: The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003, 170:1709–1716.

    Article  PubMed  CAS  Google Scholar 

  28. Eymard JC, Joly F, Priou F, et al.: Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients with hormone refractory prostate cancer: a final report [abstract]. Proc ASCO 2004, 23:4603.

    Google Scholar 

  29. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al.: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002, 94:1457–1465.

    Article  PubMed  CAS  Google Scholar 

  30. Petrylak D, Shelton G, England-Owen C, et al.: Response and preliminary survival results of a phase II study of docetaxel and estramustine in patients with androgen-independent prostate cancer [abstract]. Proc ASCO 2000, 19:1312.

    Google Scholar 

  31. Birch R, Kalman L, Holt L, et al.: Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer [abstract]. Proc ASCO 2004, 23:4622.

    Google Scholar 

  32. Tannock I, Gospodarowicz M, Meakin W, et al.: Treatment of metastatic prostate cancer with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989, 7:590–597.

    PubMed  CAS  Google Scholar 

  33. Fossa SD, Slee PH, Brausi M, et al.: Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001, 19:62–71.

    PubMed  CAS  Google Scholar 

  34. Nishimura K, Nonomura N, Satoh E, et al.: Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001, 93:1739–1746.

    Article  PubMed  CAS  Google Scholar 

  35. Eastham JA, Kelly WK, Grossfeld GD, et al.: Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 trial of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high risk localized disease. Urology 2003, 62(Suppl 1):55–62.

    Article  PubMed  Google Scholar 

  36. Glode LM: Phase III randomized study of adjuvant androgen deprivation therapy with or without mitoxantrone and prednisone after prostatectomy in patients with high risk adenocarcinoma of the prostate. http://cancer.gov/search/ viewclinicaltrials.aspx?version = healthprofessional& cdrid=67352. Accessed November 7, 2004.

  37. Pienta KJ: Radiation Therapy Oncology Group P-0014: A phase 3 randomized study of patients with high risk hormonenaïve prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. Urology 2003, 62(Suppl 6B):95–101.

    Article  PubMed  Google Scholar 

  38. Graff JR: Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 2002, 6:103–113. This review provides many of the references and rationale for targeting the PTEN/PI3K/AKT pathway, which may be important in promoting cell survival and chemotherapy and hormonal therapy resistance in advanced prostate cancer.

    Article  PubMed  CAS  Google Scholar 

  39. Chen CD, Welsbie DS, Tran C, et al.: Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33–38. This comprehensive discussion of the various means of achieving the hormone-refractory state in advanced prostate cancer is essential in formulating hypotheses to overcome these mechanisms.

    Article  PubMed  Google Scholar 

  40. McDonnell TJ, Troncoso P, Brisbay SM, et al.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940–6944.

    PubMed  CAS  Google Scholar 

  41. Dahut WL, Gulley JL, Arlen PM, et al.: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2532–2539.

    Article  PubMed  CAS  Google Scholar 

  42. Liu Y, Tohnya TM, Figg WD, et al.: Phase I study of CC-5013 (Revlimid), a thalidomide derivative in patients with refractory metastatic cancer [abstract]. Proc ASCO 2003, 22:927.

    Google Scholar 

  43. Sison B, Bond T, Amato RJ, et al.: Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer [abstract]. Proc ASCO 2004, 23:4701.

    Google Scholar 

  44. Beer TM, Eilers KM, Garzotto M, et al.: Weekly high dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21:123–128.

    Article  PubMed  CAS  Google Scholar 

  45. Chatta GS, Fakih M, Ramalingam S, et al.: Phase I pharmacokinetic study of daily imatinib in combination with docetaxel for patients with advanced solid tumors [abstract]. Proc ASCO 2004, 23:2047.

    Google Scholar 

  46. Papandreou CN, Daliani DD, Nix D, et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108–2121.

    Article  PubMed  CAS  Google Scholar 

  47. Carducci M, Nelson JB, Saad F: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study [abstract]. Proc ASCO 2004, 23:4508.

    Google Scholar 

  48. Picus J, Halabi S, Rini B, et al.: The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006 [abstract]. Proc ASCO 2003, 22:393.

    Google Scholar 

  49. Schroder FH, Wildhagen MF: ZD1839 (gefitinib) and hormone resistant prostate cancer: final results of a double blind randomized placebo-controlled phase II study. J Clin Oncol 2004, 22(14S):abstract 4698.

    Google Scholar 

  50. Chi KN, Murray RN, Gleave ME, et al.: A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients with metastatic hormone refractory prostate cancer [abstract]. Proc ASCO 2003, 22:393.

    Google Scholar 

  51. Sternberg CN, Hetherington J, Paluchowska PHTJ, et al.: Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer [abstract]. Proc ASCO 2003, 22:395.

    Google Scholar 

  52. Goodin S, Kane MP, Rubin EH: Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004, 22:2105–2125.

    Article  Google Scholar 

  53. Hussain M, Faulkner J, Vaishampayan U, et al.: Epothilone B analogue BMS-247550 administered every 21 days in patients with hormone refractory prostate cancer: a Southwest Oncology Group Study (S0111) [abstract]. Proc ASCO 2004, 23:4510.

    Google Scholar 

  54. Rosenberg JE, Galsky MD, Weinberg V, et al.: Response to second-line taxane-based therapy (BMS) in hormone refractory prostate cancer (HRPC) [abstract]. Proc ASCO 2004, 23:4564.

    Google Scholar 

  55. Tu SM, Millikan RE, Mengistu RE, et al.: Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001, 357:336–341.

    Article  PubMed  CAS  Google Scholar 

  56. Isaacs JT: The biology of hormone refractory prostate cancer: why does it develop? Urol Clin North Am 1999, 26:263–273. This review is broad in scope, timeless in its depth, and strongly recommended as a starting point for those interested in the underlying biology of prostate cancer.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, CRB 1M88, 1650 Orleans Street, 21231, Baltimore, MD, USA

    Andrew J. Armstrong MD & Michael A. Carducci MD

Authors
  1. Andrew J. Armstrong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Carducci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Armstrong, A.J., Carducci, M.A. Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. Curr Oncol Rep 7, 220–227 (2005). https://doi.org/10.1007/s11912-005-0077-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0077-y

Keywords

Search

Navigation